API | diethylamine salicylate

diethylamine salicylate Report issue

Small molecule Experimental

AACT

Active Ingredient History

NOW

Diethylamine salicylate is a salicylic acid salt, that is a cost-effective and simple, first-line treatment for rheumatic and minor musculoskeletal conditions including lumbago, fibrositis, sciatica, bruises, and strains. Salicylic acid directly and irreversibly inhibits the activity of both types of cyclo-oxygenases (COX-1 and COX-2) to decrease the formation of precursors of prostaglandins and thromboxanes from arachidonic acid. Salicylate's antirheumatic (nonsteroidal anti-inflammatory) actions are a result of its analgesic and anti-inflammatory mechanisms. ^NCATS

Chemistry

SMILES: CCNCC.OC(=O)C1=C(O)C=CC=C1
InChIKey: JGMKRAUEFASZKH-UHFFFAOYSA-N
Mol. Mass: 211.2576
ALogP: Missing data
ChEMBL Molecules: Missing data

More Chemistry

Pharmacology

Mechanism of Action:
- Prostaglandin G/H synthase 1 (Homo sapiens) ^UniProt
- Prostaglandin G/H synthase 2 (Homo sapiens) ^UniProt
Multi-specific: Missing data
Black Box: Missing data
Availability: Missing data
Delivery Methods: Missing data
Pro Drug: Missing data

esarin

Organizations (2)

Research & Development (2)

Organization	Org Type	FDA approvals	Clinical Trials involvement	Org ID	Force Sort

Marketing (0)

Organization	Org Type	FDA approvals	Clinical Trials involvement	Org ID	Force Sort

Indications (4)

Approved Indications (1)

Pain

Experimental Indications - Clinical Trial Phases 1-4 (3)

Thrombophlebitis (Phase 4)

Varicose Veins (Phase 4)

Venous Insufficiency (Phase 4)

Overview

Highest Phase: Phase 4
# of Trials: 1
# of Trial Organizations: 2

Trials by Phase

Trial	Phase	Start Date	Organizations	Indications

Feedback

Data collection and curation is an ongoing process for CDEK - if you notice any information here to be missing or incorrect, please let us know! When possible, please include a source URL (we verify all data prior to inclusion).

Report issue